Trexquant Investment LP Sells 3,839 Shares of iRadimed Corporation $IRMD

Trexquant Investment LP lowered its stake in shares of iRadimed Corporation (NASDAQ:IRMD - Free Report) by 32.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,036 shares of the medical equipment provider's stock after selling 3,839 shares during the period. Trexquant Investment LP owned 0.06% of iRadimed worth $422,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. increased its position in iRadimed by 3.3% in the first quarter. Vanguard Group Inc. now owns 554,451 shares of the medical equipment provider's stock worth $29,098,000 after purchasing an additional 17,640 shares during the last quarter. Copeland Capital Management LLC boosted its stake in shares of iRadimed by 3.2% during the first quarter. Copeland Capital Management LLC now owns 490,544 shares of the medical equipment provider's stock valued at $25,744,000 after purchasing an additional 14,981 shares during the period. Northern Trust Corp boosted its stake in shares of iRadimed by 7.3% during the fourth quarter. Northern Trust Corp now owns 143,069 shares of the medical equipment provider's stock valued at $7,869,000 after purchasing an additional 9,722 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of iRadimed by 1.6% in the first quarter. Bank of New York Mellon Corp now owns 101,665 shares of the medical equipment provider's stock valued at $5,335,000 after acquiring an additional 1,557 shares in the last quarter. Finally, Envestnet Asset Management Inc. raised its holdings in shares of iRadimed by 20.3% in the first quarter. Envestnet Asset Management Inc. now owns 70,473 shares of the medical equipment provider's stock valued at $3,698,000 after acquiring an additional 11,892 shares in the last quarter. 92.34% of the stock is owned by hedge funds and other institutional investors.

iRadimed Stock Performance

Shares of iRadimed stock opened at $71.85 on Tuesday. The company has a market capitalization of $913.93 million, a PE ratio of 44.35 and a beta of 1.01. The company has a 50-day simple moving average of $65.21 and a two-hundred day simple moving average of $58.02. iRadimed Corporation has a one year low of $44.65 and a one year high of $74.00.

iRadimed Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, August 28th. Investors of record on Monday, August 18th were given a $0.17 dividend. The ex-dividend date was Monday, August 18th. This represents a $0.68 dividend on an annualized basis and a yield of 0.9%. iRadimed's dividend payout ratio is currently 41.98%.

Insider Buying and Selling

In related news, Director Monty K. Allen sold 1,102 shares of the company's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $69.10, for a total value of $76,148.20. Following the sale, the director owned 19,898 shares in the company, valued at $1,374,951.80. This represents a 5.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 36.80% of the stock is currently owned by corporate insiders.

About iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.